针对帕金森病的认知障碍进行基于多模式认知治疗:药物,运动,非侵入性脑刺激和技术
Elisa Mantovani1, Miriana Maria Bressan, Michele Tinazzi
1Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy.
Current opinion in neurology
|August 12, 2024
概括
帕金森病 (PD) 的认知障碍可能会通过联合疗法得到改善. 包括运动,大脑刺激和技术在内的多式干预措施与认知训练一起,对PD患者显示出有前途的结果.
科学领域:
- 神经学 神经学
- 神经康复疗法 神经康复疗法
背景情况:
- 认知障碍是帕金森病 (PD) 的一个显著的非运动症状,影响了疾病的所有阶段.
- 目前,对于PD相关的认知障碍,还没有确定的药理疗法.
- 基于认知的干预措施提供了一个潜在的改善途径.
研究的目的:
- 审查基于多模式认知的干预措施对帕金森病认知障碍的有效性.
- 探索将各种非药理学和药理学方法与认知治疗相结合的潜力.
主要方法:
- 对帕金森病的基于认知的干预措施的现有证据的审查.
- 分析多模式方法,包括认知训练,运动,非侵入性脑刺激和基于技术的干预措施.
主要成果:
- 运动与认知训练相结合,可以增强整体,记忆,视觉空间和执行功能.
- 经直流刺激与认知训练有助于提高注意力和执行功能.
- 虚拟现实和远程康复与认知训练相结合,改善了PD患者的全球和执行功能.
结论:
- 初步证据强烈支持将药理学和非药理学干预措施与基于认知的PD治疗相结合.
- 为未来的临床试验提出了建议,以解决局限性问题,并进一步研究PD认知障碍的综合疗法.
相关概念视频
Parkinson's Disease: Treatment
241
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
241
Parkinson's Disease: Overview
508
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
508
Alzheimer's Disease: Treatment
171
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
171
Alzheimer's Disease: Overview
456
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
456
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
112
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
112


